AU4918796A - Methods of treating or preventing psychiatric disorders - Google Patents

Methods of treating or preventing psychiatric disorders

Info

Publication number
AU4918796A
AU4918796A AU49187/96A AU4918796A AU4918796A AU 4918796 A AU4918796 A AU 4918796A AU 49187/96 A AU49187/96 A AU 49187/96A AU 4918796 A AU4918796 A AU 4918796A AU 4918796 A AU4918796 A AU 4918796A
Authority
AU
Australia
Prior art keywords
treating
methods
psychiatric disorders
preventing psychiatric
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU49187/96A
Inventor
Kirk W. Johnson
Lee A Phebus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU4918796A publication Critical patent/AU4918796A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU49187/96A 1995-02-10 1996-02-08 Methods of treating or preventing psychiatric disorders Abandoned AU4918796A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US387056 1989-07-28
US38705695A 1995-02-10 1995-02-10
PCT/US1996/001737 WO1996024353A1 (en) 1995-02-10 1996-02-08 Methods of treating or preventing psychiatric disorders

Publications (1)

Publication Number Publication Date
AU4918796A true AU4918796A (en) 1996-08-27

Family

ID=23528275

Family Applications (1)

Application Number Title Priority Date Filing Date
AU49187/96A Abandoned AU4918796A (en) 1995-02-10 1996-02-08 Methods of treating or preventing psychiatric disorders

Country Status (2)

Country Link
AU (1) AU4918796A (en)
WO (1) WO1996024353A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023455A1 (en) * 1995-12-21 1997-07-03 Eli Lilly And Company Processes for preparing non-peptidyl tachykinin receptor antagonists
AU2898297A (en) * 1996-05-24 1998-01-05 Novartis Ag Use of substance p antagonists for treating social phobia
US6117855A (en) 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
AU726745B2 (en) * 1996-10-07 2000-11-16 Merck Sharp & Dohme Limited CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
US6100256A (en) * 1996-12-02 2000-08-08 Merck Sharp & Dohme Ltd. Use of NK-1 receptors antagonists for treating schizophrenic disorders
EP0942733B1 (en) * 1996-12-02 2005-04-27 MERCK SHARP & DOHME LTD. Use of nk-1 receptor antagonists for treating cognitive disorders
AU731349B2 (en) * 1996-12-02 2001-03-29 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating sexual dysfunctions
ATE282417T1 (en) * 1996-12-02 2004-12-15 Merck Sharp & Dohme THE USE OF NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MOVEMENT DISORDERS
US5977104A (en) * 1996-12-02 1999-11-02 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating bipolar disorders
AU731672B2 (en) * 1996-12-02 2001-04-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating bipolar disorders
ES2231901T3 (en) * 1996-12-02 2005-05-16 MERCK SHARP & DOHME LTD. USE OF NK-1 RECEIVER ANTAGONISTS TO TREAT DISORDERS FOR THE USE OF SUBSTANCES.
US6613765B1 (en) 1996-12-02 2003-09-02 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating major depressive disorders
JP2001524960A (en) * 1997-04-24 2001-12-04 メルク シヤープ エンド ドーム リミテツド Use of an NK-1 receptor antagonist to treat an eating disorder
CA2287397A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist and an ssri for treating obesity
AU8297698A (en) * 1997-07-10 1999-02-08 Eli Lilly And Company Inhibitors of neutrophil mediated oxidant production
WO1999007375A1 (en) * 1997-08-04 1999-02-18 Merck Sharp & Dohme Limited Use of nk-1 receptor antagonists for treating aggressive behaviour disorders
AU738047B2 (en) * 1997-08-04 2001-09-06 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating mania
GB9716457D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
GB9716463D0 (en) * 1997-08-04 1997-10-08 Merck Sharp & Dohme Therapeutic agents
JP2001513562A (en) * 1997-08-28 2001-09-04 メルク エンド カムパニー インコーポレーテッド How to treat premenstrual or late luteal syndrome
US6271230B1 (en) 1997-12-01 2001-08-07 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating cognitive disorders
US6087348A (en) * 1997-12-01 2000-07-11 Merck Sharp & Dohme Ltd. Use of NK-1 receptor antagonists for treating stress disorders
US6156749A (en) * 1997-12-01 2000-12-05 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
GB9812662D0 (en) * 1998-06-11 1998-08-12 Merck Sharp & Dohme Therapeutic use
PT1107744E (en) 1998-08-25 2003-08-29 Wolfgang Mueller USE OF ANTAGONISTS OF THE P-SUBSTANCE FOR THE TREATMENT OF CHRONIC FAILURE SYNDROME AND / OR FIBROMYALGIA
AR021155A1 (en) * 1999-07-08 2002-06-12 Lundbeck & Co As H TREATMENT OF NEUROTIC DISORDERS
ATE318135T1 (en) 1999-09-03 2006-03-15 Apbi Holdings Llc USE OF DAPOXETINE, A RAPID ONSET SELECTIVE SEROTONIN UPtake INHIBITOR, FOR THE TREATMENT OF SEXUAL DYSFUNCTION
CA2324813A1 (en) * 1999-11-10 2001-05-10 Susan Beth Sobolov-Jaynes Combination treatment for depression and anxiety
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
CA2412355A1 (en) * 2000-06-12 2001-12-20 University Of Rochester Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist
WO2003101459A1 (en) * 2002-05-29 2003-12-11 The Regents Of The University Of California Antagonizing nk1 receptors inhibits consumption of substances of abuse
FR2912057B1 (en) * 2007-02-07 2009-04-17 Sanofi Aventis Sa PHARMACEUTICAL COMPOSITION COMPRISING SAREDUTANT AND A SELECTIVE SEROTONIN RECAPTURE INHIBITOR OR SEROTONIN / NOREPINEPHRINE RECAPTURE INHIBITOR
CA2655212C (en) 2006-06-16 2012-07-31 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
GB0708186D0 (en) * 2007-04-27 2007-06-06 Merck Sharp & Dohme Therapeutic compounds
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296497A (en) * 1989-05-16 1994-03-22 Duphar International Research B.V. 3,4-dehydropiperidine derivatives having psychotropic activity
US5444074A (en) * 1992-04-15 1995-08-22 Merck Sharp & Dohme Limited Piperidine tachykinin receptor antagonists

Also Published As

Publication number Publication date
WO1996024353A1 (en) 1996-08-15

Similar Documents

Publication Publication Date Title
AU4918796A (en) Methods of treating or preventing psychiatric disorders
ZA965088B (en) Methods of preventing or treating allergles
AU7443496A (en) Treatment of migraine
AU5750796A (en) System for the treatment of insomnia
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
ZA966240B (en) Methods for treatment of allergic asthma.
AUPN271295A0 (en) Method of treatment
EP0820467A4 (en) Methods of treating disorders of the eye
AU2103295A (en) Methods for the treatment of thrombosis
EP0729361A4 (en) Method of treating neurological disorders
AU4372597A (en) Method for the treatment of neurological or neuropsychiatric disorders
AU8156094A (en) Methods of inhibiting breast disorders
AU2251897A (en) Method of treating liver disorders
AU5528996A (en) Methods of treating or preventing pain or nociception
AU5198898A (en) Method for treatment of glutamate related disorders
PL327144A1 (en) Method of relieving paints
AU6927894A (en) 4-amidinophenylsulphonamides for the treatment of thrombo-embolitic conditions
ZA965346B (en) Methods of treating neuropeptide Y-associated conditions.
AU7113996A (en) Methods of treating beta-amyloid-associated conditions
AU5676496A (en) Method of treating endotoxic shock
AU6953094A (en) Methods and compositions for treating depression and other psychiatric disorders
AU2874497A (en) Balanites aegyptiaca method of treatment
GB9507825D0 (en) Method of treatment
AU7349496A (en) Method for treatment of SLE
AU1097995A (en) Combination method for the treatment of patterned alopecia